Publicações

A Randomized Phase Ii Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared with Ridaforolimus and Exemestane in Patients with Advanced Breast Cancer

AuthID
P-00N-1B3

Author(s)

Rugo, HS

Tredan, O

Ro, J

Morales, SM

Campone, M

Musolino, A

Afonso, N

Ferreira, M

Park, KH

Cortes, J

Tan, AR

Blum, JL

Eaton, L

Gause, CK

Wang, Z

Im, E

Mauro, DJ

Jones, MB

Denker, A

Baselga, J

Document Type

Article

Year published

2017

Published

in BREAST CANCER RESEARCH AND TREATMENT, ISSN: 0167-6806

Volume: 165, Issue: 3, Pages: 601-609 (9)

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1007/s10549-017-4375-5

Wos: WOS:000411105800015

Source Identifiers

ISSN: 0167-6806

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

A Randomized Phase Ii Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared with Ridaforolimus and Exemestane in Patients with Advanced Breast Cancer

Useful Links

Get Help

Autenticação Federada (Click on the image)

A Randomized Phase Ii Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared with Ridaforolimus and Exemestane in Patients with Advanced Breast Cancer

Useful Links

Get Help